A paradigm shift…
Driven by the changing landscape of healthcare, advances in technology and more stringent regulation, life science companies continue to adapt and transform in the pursuit of delivering life changing medicines to patients while satisfying the demands of shareholders.
While the infrastructure of life science organizations may vary based on a multitude of factors, there is a standard operational framework that exists in most. But as healthcare ecosystems change and accountable care and value-based medicine is on the rise, safety and efficacy are no longer sufficient to attract investors and support physician and patient success. At the mercy of both government and private payers, life science companies must focus and improve their ability to articulate the ‘value’ of a therapeutic intervention in defining a brand strategy.
Understanding unmet needs in a therapeutic area, depicting the patient journey step-by-step, impacting current treatment paradigms and operating compliantly within various regulatory environments are key success factors in optimizing patient success and shareholder value.
What role can Medical Affairs play in shifting focus to value?
To read the complete article, use the link below to view and/or download.